1-5 of 5
Liv Meert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3675.
https://doi.org/10.1182/blood.V124.21.3675.3675
Published: 2014
Journal Articles

Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups

Sergio Amadori, MD, Stefan Suciu, PhD, Dominik Selleslag, MD, Elena Rossetti, MD, Gianluca Gaidano, MD PhD, Maurizio Musso, MD, Luciana Annino, MD, Adriano Venditti, Domenico Magro, MD, Paolo de Fabritiis, MD, Petra Muus, MD, Giuliana Alimena, MD, Marco Mancini, Anne Hagemeijer, MD, Francesca Cotugno, Marco Vignetti, MD, Paola Fazi, MD, Liv Meert, MSc, Safaa M Ramadan, MD PhD, Roelof Willemze, MD PhD, Theo de Witte, MD, Frederic Baron
Journal: Blood
Blood (2014) 124 (21): 619.
https://doi.org/10.1182/blood.V124.21.619.619
Published: 2014
Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD
Journal: Blood
Blood (2013) 122 (21): 829.
https://doi.org/10.1182/blood.V122.21.829.829
Published: 2013
Journal Articles

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

Michael Lübbert, MD, Stefan Suciu, Anne Hagemeijer, Ljudmila Bogatyreva, Björn Rüter, Uwe Platzbecker, MD, Aristoteles Giagounidis, MD, Dominik Selleslag, Boris Labar, MD, PhD, Ulrich Germing, MD, Helmut R Salih, MD, Liv Meert, Petra Muus, MD, PhD, Karl-Heinz Pflüger, MD, Andrea Kuendgen, Carlo Aul, Theo M. de Witte, Arnold Ganser, Jean-Pierre Marie, Pierre W. Wijermans
Journal: Blood
Blood (2012) 120 (21): 2804.
https://doi.org/10.1182/blood.V120.21.2804.2804
Published: 2012
Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061/AML-14A trial)

Roelof Willemze, MD, PhD, Petra Muus, MD, PhD, Stijn J.M. Halkes, Giovanna Meloni, MD, Stefan Suciu, Liv Meert, Jocelyne Flament, Matthias Karrasch, Marco Vignetti, Sergio Amadori, MD, Theo M. de Witte, MD, Jean-Pierre Marie, MD
Journal: Blood
Blood (2011) 118 (21): 2610.
https://doi.org/10.1182/blood.V118.21.2610.2610
Published: 2011